MCID: PRR013
MIFTS: 40

Prurigo Nodularis

Categories: Rare diseases, Skin diseases

Aliases & Classifications for Prurigo Nodularis

MalaCards integrated aliases for Prurigo Nodularis:

Name: Prurigo Nodularis 53 55 73
Nodular Prurigo 53

Classifications:



External Ids:

ICD10 33 L28.1
UMLS 73 C0263353

Summaries for Prurigo Nodularis

NIH Rare Diseases : 53 Prurigo nodularis (PN) is a skin disease that causes hard, itchy lumps (nodules) to form on the skin. The itching (pruritus) can be intense, causing people to scratch themselves to the point of bleeding or pain. Scratching can cause more skin lesions to appear. The itching is worsened by heat, sweating, or irritation from clothing. In some cases, people with PN have a history of other diseases including eczema (atopic dermatitis), lymphoma, HIV infection, severe anemia, or kidney disease.  The exact cause of PN is unknown. Although scratching is known to cause more nodules to appear, it is unclear what causes the itching to develop in the first place. Diagnosis of the disease is based on observing signs such as extremely itchy skin with the formation of nodules. In some cases, a skin biopsy is used to confirm the diagnosis. Treatment may include corticosteroid creams, oral medications, cryotherapy, or photochemotherapy.

MalaCards based summary : Prurigo Nodularis, also known as nodular prurigo, is related to amyloidosis, primary localized cutaneous, 2 and amyloidosis, primary localized cutaneous, 1. An important gene associated with Prurigo Nodularis is RNASE3 (Ribonuclease A Family Member 3), and among its related pathways/superpathways are Phospholipase-C Pathway and p70S6K Signaling. The drugs Nalbuphine and Peripheral Nervous System Agents have been mentioned in the context of this disorder. Affiliated tissues include skin, kidney and tonsil.

Wikipedia : 76 Prurigo nodularis (PN), also known as nodular prurigo, is a skin disease characterised by pruritic... more...

Related Diseases for Prurigo Nodularis

Diseases related to Prurigo Nodularis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 83)
# Related Disease Score Top Affiliating Genes
1 amyloidosis, primary localized cutaneous, 2 11.1
2 amyloidosis, primary localized cutaneous, 1 11.1
3 epidermolysis bullosa pruriginosa 11.1
4 dermatitis 10.3
5 cough variant asthma 10.2 NGF RNASE3
6 lymphoma 10.2
7 conjunctival nevus 10.2 NGF RNASE3
8 ocular cicatricial pemphigoid 10.2 NGF RNASE3
9 bullous pemphigoid 10.2
10 neuropathy 10.2
11 keratoacanthoma 10.2
12 hepatitis 10.2
13 tonsillitis 10.2
14 ocular dominance 10.1 NGF NGFR
15 anhidrosis 10.1 NGF NGFR
16 herpes zoster 10.1
17 lichen planus 10.1
18 neurodermatitis 10.1
19 linear iga disease 10.1
20 lymphoma, hodgkin, classic 10.1
21 depression 10.1
22 uremia 10.1
23 keratoconjunctivitis 10.1 NGF RNASE3
24 lymphoma, non-hodgkin, familial 9.9
25 squamous cell carcinoma 9.9
26 dermatitis herpetiformis 9.9
27 psoriasis 7 9.9
28 hepatitis c 9.9
29 anxiety 9.9
30 neuroma 9.9
31 psoriasis 11 9.9
32 granular cell tumor 9.9
33 vasculitis 9.9
34 gastric cancer 9.9
35 transitional cell carcinoma 9.9
36 psoriasis 9.9
37 psoriasis 13 9.9
38 contact dermatitis 9.9
39 amyloidosis 9.9
40 burns 9.9
41 allergic contact dermatitis 9.9
42 hemangioma 9.9
43 cytomegalic inclusion disease 9.9
44 hashimoto thyroiditis 9.9
45 igg4-related disease 9.9
46 celiac disease 1 9.9
47 porokeratosis 9.9
48 colitis 9.9
49 bladder urothelial carcinoma 9.9
50 collagenous colitis 9.9

Graphical network of the top 20 diseases related to Prurigo Nodularis:



Diseases related to Prurigo Nodularis

Symptoms & Phenotypes for Prurigo Nodularis

Drugs & Therapeutics for Prurigo Nodularis

Drugs for Prurigo Nodularis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 57)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nalbuphine Approved Phase 2, Phase 3,Phase 3 20594-83-6 5360630 5311304
2 Peripheral Nervous System Agents Phase 2, Phase 3,Phase 3,Not Applicable
3 Analgesics Phase 2, Phase 3,Phase 3
4 Central Nervous System Depressants Phase 2, Phase 3,Phase 3
5 Narcotic Antagonists Phase 2, Phase 3,Phase 3
6 Narcotics Phase 2, Phase 3,Phase 3
7 Analgesics, Opioid Phase 2, Phase 3,Phase 3
8 Antipruritics Phase 2, Phase 3,Phase 3
9
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
10
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
11
Pimecrolimus Approved, Investigational Phase 2 137071-32-0 6447131 17753757
12
Apremilast Approved, Investigational Phase 2 608141-41-9 11561674
13
Substance P Investigational Phase 2 33507-63-0 44359816
14
Butyric Acid Experimental, Investigational Phase 2 107-92-6 264
15 Serlopitant Investigational Phase 2 860642-69-9
16 Neurotransmitter Agents Phase 2,Not Applicable
17 neurokinin A Phase 2
18 Neurokinin-1 Receptor Antagonists Phase 2
19 Cortisol succinate Phase 2
20 Analgesics, Non-Narcotic Phase 2
21 Dermatologic Agents Phase 2
22 Angiogenesis Inhibitors Phase 2
23 Angiogenesis Modulating Agents Phase 2
24 Hydrocortisone 17-butyrate 21-propionate Phase 2
25 Hydrocortisone acetate Phase 2
26 Hydrocortisone-17-butyrate Phase 2
27 Anti-Bacterial Agents Phase 2,Not Applicable
28 Immunosuppressive Agents Phase 2
29 Anti-Infective Agents Phase 2,Not Applicable
30 Anti-Inflammatory Agents Phase 2
31 Anti-Inflammatory Agents, Non-Steroidal Phase 2
32 Antirheumatic Agents Phase 2
33 Calcineurin Inhibitors Phase 2
34
Citalopram Approved Not Applicable 59729-33-8 2771
35
Dapsone Approved, Investigational Not Applicable 80-08-0 2955
36
leucovorin Approved, Nutraceutical Not Applicable 58-05-9 143 6006
37
Folic Acid Approved, Nutraceutical, Vet_approved Not Applicable 59-30-3 6037
38 Cholinergic Agents Not Applicable
39 Muscarinic Antagonists Not Applicable
40 Cholinergic Antagonists Not Applicable
41 Serotonin Agents Not Applicable
42 Serotonin Uptake Inhibitors Not Applicable
43 Neurotransmitter Uptake Inhibitors Not Applicable
44 Parasympatholytics Not Applicable
45 Antidepressive Agents Not Applicable
46 Antidepressive Agents, Second-Generation Not Applicable
47 Antiparkinson Agents Not Applicable
48 Psychotropic Drugs Not Applicable
49 Autonomic Agents Not Applicable
50 Folic Acid Antagonists Not Applicable

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis Completed NCT02174419 Phase 2, Phase 3 nalbuphine HCl ER tablets 90 mg BID;nalbuphine HCl ER tablets 180 mg BID;Placebo tablets BID
2 Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis Recruiting NCT03546816 Phase 3 5mg Serlopitant Tablets;Placebo Tablets
3 Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch) Recruiting NCT03540160 Phase 3 5 mg Serlopitant Tablets
4 Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis Active, not recruiting NCT02174432 Phase 2, Phase 3 nalbuphine HCl ER 90 mg BID;nalbuphine HCl ER 120 mg BID;nalbuphine HCl ER 180 mg BID
5 PRISM Study-Pruritus Relief Through Itch Scratch Modulation Not yet recruiting NCT03497975 Phase 2, Phase 3 Nalbuphine ER Tablets
6 A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN) Completed NCT02196324 Phase 2 serlopitant;Placebo
7 Safety and Efficacy of CC-10004 for Prurigo Nodularis Completed NCT00869089 Phase 2 CC-10004
8 Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease Completed NCT00507832 Phase 2 Pimecrolimus;Hydrocortisone;Pimecrolimus
9 Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis Recruiting NCT03576287 Phase 1, Phase 2 Apremilast Oral Product
10 Safety and Efficacy of Nemolizumab in PN Not yet recruiting NCT03181503 Phase 2 CD14152 Dose A;CD14152 placebo
11 Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis Unknown status NCT00532519 Not Applicable citalopram (cipralex)
12 Dapsone Prurigo Study Not yet recruiting NCT01870050 Not Applicable Dapsone gel - verum

Search NIH Clinical Center for Prurigo Nodularis

Genetic Tests for Prurigo Nodularis

Anatomical Context for Prurigo Nodularis

MalaCards organs/tissues related to Prurigo Nodularis:

41
Skin, Kidney, Tonsil, Endothelial, Neutrophil, Testes, Thyroid

Publications for Prurigo Nodularis

Articles related to Prurigo Nodularis:

(show top 50) (show all 186)
# Title Authors Year
1
The use of biodegradable microneedle patches to increase penetration of topical steroid for prurigo nodularis. ( 29521638 )
2018
2
Ethnic differences and comorbidities of 909 Prurigo Nodularis patients. ( 29733939 )
2018
3
Prurigo Nodularis and Its Management. ( 29929592 )
2018
4
Generalized eruptive keratoacanthoma with vitiligo followed by the development of prurigo nodularis: A case report and published work review. ( 29058335 )
2018
5
Thalidomide for the treatment of chronic refractory prurigo nodularis. ( 29634881 )
2018
6
Rapid improvement of prurigo nodularis with cyclosporine treatment. ( 29438756 )
2018
7
Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need. ( 29869425 )
2018
8
There is no functional small-fibre neuropathy in prurigo nodularis despite neuroanatomical alterations. ( 28370394 )
2017
9
Acquired elastotic hemangioma-like changes and eccrine sweat duct squamous metaplasia in lichen simplex chronicus/prurigo nodularis-like lesions of the knee and elbow. ( 28374436 )
2017
10
Prurigo Nodularis ( 29083653 )
2017
11
Use of Isoquercetin in the Treatment of Prurigo Nodularis. ( 29141065 )
2017
12
Acquired Reactive Perforating Dermatosis is a Variant of Prurigo Nodularis. ( 27349279 )
2016
13
Hypertrophic lichen planus versus prurigo nodularis: a dermoscopic perspective. ( 27222766 )
2016
14
Treatment of prurigo nodularis with lenalidomide. ( 27891738 )
2016
15
Phototherapy for the treatment of prurigo nodularis: a review. ( 27617458 )
2016
16
Treatment of prurigo nodularis with dexamethasone-cyclophosphamide pulse therapy. ( 26924412 )
2016
17
Aspirin and loxoprofen relieve refractory pruritus in patients with prurigo nodularis. ( 26970197 )
2016
18
Treatment of prurigo nodularis with dexamethasone-cyclophosphamide pulse therapy. ( 26858054 )
2016
19
A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo Nodularis. ( 27289372 )
2016
20
Anxiety, depression and suicide in patients with prurigo nodularis. ( 27505149 )
2016
21
Bullous pemphigoid developed in a patient with prurigo nodularis. ( 27511319 )
2016
22
Systemic methotrexate for prurigo nodularis and keratoacanthomas in actinically damaged skin. ( 27486591 )
2016
23
Prurigo Nodularis Management. ( 27578077 )
2016
24
Successful use of a modified Goeckerman regimen in the treatment of generalized prurigo nodularis. ( 25497953 )
2015
25
Intraepidermal Nerve Fibre Density is Decreased in Lesional and Inter-lesional Prurigo Nodularis and Reconstitutes on Healing of Lesions. ( 26338533 )
2015
26
Prurigo nodularis: Picking the right treatment. ( 25973448 )
2015
27
Serotonin and interleukin-6: Association with pruritus severity, sleep quality and depression severity in Prurigo Nodularis. ( 26277226 )
2015
28
Biopsychosocial Factors Associated with Prurigo Nodularis in Endogenous Eczema. ( 26538749 )
2015
29
The pathogenesis of Prurigo nodularis - 'Super-Itch' in exploration. ( 26416433 )
2015
30
Prurigo nodularis after acupuncture. ( 27051775 )
2015
31
Dermoscopy of prurigo nodularis. ( 25808786 )
2015
32
Oral Tacrolimus Treatment of Pruritus in Prurigo Nodularis. ( 25804254 )
2015
33
Persistent prurigo nodularis in HIV-infected patient responsive to antiretroviral therapy with raltegravir. ( 24479440 )
2014
34
Paraphenylenediamine dye allergic contact dermatitis of mustache region manifesting as prurigo nodularis-like lesions. ( 24603506 )
2014
35
Prurigo nodularis in a peritoneal dialysis patient. ( 24380918 )
2014
36
Intractable prurigo nodularis successfully treated with combination therapy with a newly developed excimer laser and topical steroids. ( 24945654 )
2014
37
Prurigo nodularis: retrospective study of 13 cases managed with methotrexate. ( 24825138 )
2014
38
Prurigo nodularis as index symptom of (non-Hodgkin) lymphoma: ultrasound as a helpful diagnostic tool in dermatological disorders of unknown origin. ( 24697249 )
2014
39
Prurigo nodularis and Hashimoto thyroiditis. ( 25446192 )
2014
40
Extensive prurigo nodularis: characterization and etiology. ( 24662043 )
2014
41
Oral ketotifen and topical antibiotic therapy in the management of pruritus in prurigo nodularis: a randomized, controlled, single-blind, parallel study. ( 24082179 )
2013
42
Prurigo nodularis-like skin eruptions in a patient with IgG4-related disease. ( 24001614 )
2013
43
Prurigo nodularis and dialyzer membrane. ( 23676832 )
2013
44
Evaluation of the Antipruritic Effects of Topical Pimecrolimus in Non-Atopic Prurigo Nodularis: Results of a Randomized, Hydrocortisone-Controlled, Double-Blind Phase II Trial. ( 24281309 )
2013
45
Prurigo nodularis: an update on etiopathogenesis and therapy. ( 23767411 )
2013
46
Combination therapy of fexofenadine and montelukast is effective in prurigo nodularis and pemphigoid nodularis. ( 24102897 )
2013
47
Successful treatment of chronic intractable itching using oral pregabalin in a patient with diabetes and systemic prurigo nodularis: a case report of an iliopsoas muscle abscess. ( 24292753 )
2013
48
Treatment of prurigo nodularis with pregabalin. ( 23013514 )
2013
49
Use of lenalidomide in treating refractory prurigo nodularis. ( 23545923 )
2013
50
Linear IgA bullous dermatosis with a prurigo nodularis-like appearance. ( 23306219 )
2013

Variations for Prurigo Nodularis

Expression for Prurigo Nodularis

Search GEO for disease gene expression data for Prurigo Nodularis.

Pathways for Prurigo Nodularis

GO Terms for Prurigo Nodularis

Cellular components related to Prurigo Nodularis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.46 NGF RNASE3 SEMA3A TAC1
2 axon GO:0030424 9.13 NGF SEMA3A TAC1
3 extracellular region GO:0005576 9.02 NGF NGFR RNASE3 SEMA3A TAC1

Biological processes related to Prurigo Nodularis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.4 NGF NGFR
2 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.37 NGF NGFR
3 negative regulation of neuron projection development GO:0010977 9.32 NGFR SEMA3A
4 positive regulation of axonogenesis GO:0050772 9.26 NGF NGFR
5 nerve development GO:0021675 9.16 NGF SEMA3A
6 neurotrophin TRK receptor signaling pathway GO:0048011 8.96 NGF NGFR
7 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 8.62 NGF NGFR

Sources for Prurigo Nodularis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....